Quarterly ResultAug 5, 2026, 04:22 PM
Nyxoah Q2 Revenue €7.7M, +21% Seq; H1 Revenue €14.0M
AI Summary
Nyxoah SA reported strong Q2 2026 financial and operating results, with global net revenue reaching €7.7 million, a 21% sequential increase. U.S. net revenue grew 22% sequentially to €5.2 million, driven by continued commercial execution and a 100% prior authorization approval rate. The company secured $110 million in financing during the quarter, ending with €97.8 million in cash and equivalents. Nyxoah reaffirmed its full-year 2026 revenue guidance of €36 million to €40 million.
Key Highlights
- Q2 2026 Global net revenue: €7.7 million, a 21% sequential increase over Q1 2026.
- Q2 2026 U.S. net revenue: €5.2 million, a 22% sequential increase over Q1 2026.
- H1 2026 Global net revenue: €14.0 million, compared to €2.4 million for H1 2025.
- Secured $110 million in aggregate financing during Q2 2026.
- Cash and cash equivalents and financial assets totaled €97.8 million as of June 30, 2026.
- 427 patients actively under prior authorization entering Q3 2026, a 77% increase.
- Full-year 2026 worldwide net revenue guidance reaffirmed at €36 million to €40 million.
- Full-year 2026 total operating expenses guidance increased to €99 million to €102 million.
Price Impact
More from NYXH